OncRef

Clinical Trial: NCT04129502

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Status:

COMPLETED

Phase:

Phase 3

Lead Sponsor:Takeda
Information Provided By:Takeda
Last Update Posted:2026-10-23

Study Overview

Brief Summary

The purpose of this study is to compare effectiveness of TAK-788 as first-line treatment with that of platinum-based chemotherapy in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors has epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Participants will be randomly assigned to one of the two treatment groups- TAK-788 group or Platinum-based chemotherapy group.

Participants will receive TAK-788 orally and pemetrexed/cisplatin or pemetrexed/carboplatin via vein until the participants experience worsening disease (PD) as assessed by blinded independent review committee (IRC), intolerable harmful effects or another discontinuation criteria.

Official Title

A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations

Conditions

Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Intervention / Treatment

  • Drug: TAK-788
  • Drug: Pemetrexed
  • Drug: Cisplatin
  • Drug: Carboplatin

Other Study ID Numbers

  • TAK-788-3001
  • NL20191212
  • 2019-001845-42
  • U1111-1232-6059
  • jRCT2071210098
  • 2019

Start Date (Actual)

2020-01-10

Primary Completion Date (Actual)

2026-09-22

Study Completion Date (Actual)

2026-09-22

Enrollment (Actual)

354

Study Type

Interventional

Phase

Phase 3